American Association for Cancer Research
Browse
15357163mct072232-sup-mct-07-2232--suppl_fig_1.pdf (223.76 kB)

Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Download (223.76 kB)
journal contribution
posted on 2023-03-31, 23:13 authored by Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Paul A. Ellis, Erin Trachet, Amy M. Delaney, Patricia J. Harvey, Teresa A. Ellis, Danielle M. Amato, James M. Nelson, David W. Fry, Tong Zhu, Cho-Ming Loi, Stephen A. Fakhoury, Kevin M. Schlosser, Karen E. Sexton, R. Thomas Winters, Jessica E. Reed, Alex J. Bridges, Daniel J. Lettiere, Deborah A. Baker, Jianxin Yang, Helen T. Lee, Haile Tecle, Patrick W. Vincent
Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

History

ARTICLE ABSTRACT

Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments. PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clinical trials. PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members. Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) associated with resistance to gefitinib and erlotinib. Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880–9]

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC